DGIdb - OLAPARIB Drug Record

OLAPARIB chembl:CHEMBL521686 ApprovedAntineoplasticImmunotherapy

Alternate Names:

LYNPARZA
AZ2281
AZD-2281
AZ-2281
KU-0059436
OLAPARIB
AZD2281
KEYLYNK-010 COMPONENT OLAPARIB
OLAPARIB COMPONENT OF KEYLYNK-010
KU-59436
4-(3-{[4-(CYCLOPROPYLCARBONYL)PIPERAZIN-1-YL]CARBONYL}-4-FLUOROBENZYL)PHTHALAZIN-1(2H)-ONE
KU59436
1-(CYCLOPROPYLCARBONYL)-4-[5-[(3,4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL]-2-FLUOROBENZOYL]PIPERAZINE
LYNPARZA®
pubchem.compound:23725625
drugbank:09074
rxcui:1597582
chembl:CHEMBL521686
chemidplus:763113-22-0

Drug Info:

FDA Approval	Ovarian cancer (with BRCA mutation)
Drug Class	Small molecule inhibitor

(9 More Sources)

Publications:

Wang et al., 2016, Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer., Oncotarget
Frankum et al., 2015, Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity., Oncotarget
Mo et al., 2016, mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer., Clin. Cancer Res.
Drost et al., 2011, BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance., Cancer Cell
Drost et al., 2016, BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1., J. Clin. Invest.
Hunter et al., 2014, Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer., Mol. Cancer Ther.
Kaufman et al., 2015, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation., J. Clin. Oncol.
Tutt et al., 2010, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial., Lancet
2017 Aug 9, Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation., N Engl J Med
Gelmon et al., 2011, Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study., Lancet Oncol.
Liu et al., 2014, Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study., Lancet Oncol.
Fong et al., 2009, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers., N. Engl. J. Med.
Robson et al., 2017, Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation., N. Engl. J. Med.
Goff, 2013, Advanced ovarian cancer: what should be the standard of care?, J Gynecol Oncol
Golan T et al., 2019, Maintenance Olaparib for Germline <i>BRCA</i>-Mutated Metastatic Pancreatic Cancer., N Engl J Med
Marshall CH et al., 2019, Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations., Eur Urol
Moore K et al., 2018, Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer., N Engl J Med
Ledermann J et al., 2014, Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial., Lancet Oncol
Caulfield SE et al., 2019, Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a <i>BRCA</i>1/2 Mutation., J Adv Pract Oncol
Bajrami et al., 2014, Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity., Cancer Res.
Sulkowski et al., 2017, 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity., Sci Transl Med
Verhagen et al., 2015, Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells., Radiother Oncol
Kubota et al., 2014, Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines., Cell Cycle
Mateo et al., 2015, DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer., N. Engl. J. Med.
Williamson et al., 2010, ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors., Mol. Cancer Ther.
Weston et al., 2010, The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo., Blood
Bang et al., 2015, Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer., J. Clin. Oncol.
Schmitt et al., 2017, ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma., Cancer Res.
Moroi et al., 1975, Comparison between procaine and isocarboxazid metabolism in vitro by a liver microsomal amidase-esterase., Biochem. Pharmacol.
Poole-Wilson et al., 1975, Effect of pH on ionic exchange and function in rat and rabbit myocardium., Am. J. Physiol.
de Bono J et al., 2020, Olaparib for Metastatic Castration-Resistant Prostate Cancer., N Engl J Med
Valiakhmetova A et al., 2020, Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response., Oncologist
Stachelek et al., 2015, YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors., Mol. Cancer Res.
Kortmann et al., 2011, Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts., Clin. Cancer Res.
Shah et al., 1975, Cardiovascular effects of beta-receptor stimulants in healthy volunteers., Indian Heart J
Akamatsu et al., 1975, Increase in acetyl CoA synthetase activity after phenobarbital treatment., Biochem. Pharmacol.
Tan et al., 1975, Characteristics of the dephosphorylated form of phosphorylase purified from rat liver and measurement of its activity in crude liver preparations., Biochim. Biophys. Acta
1991, Thallium scintigraphy., Lancet
Menear et al., 2008, 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1., J. Med. Chem.
Kivlin CM et al., 2016, Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor., Cancer Biol Ther
Pignochino Y et al., 2017, PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models., Mol Cancer
Gilabert M et al., 2014, Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib., PLoS One
Parrotta R et al., 2017, A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair., J Thorac Oncol
Peña-Llopis S et al., 2012, BAP1 loss defines a new class of renal cell carcinoma., Nat Genet
Sen et al., 2017, CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib., Cancer Res.
Solomon et al., 2011, Mutational inactivation of STAG2 causes aneuploidy in human cancer., Science
Bailey et al., 2014, Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition., Mol. Cancer Ther.
Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.
Okazaki et al., 2017, Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers., J. Clin. Invest.
Ozden O et al., 2016, Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer., Sci Rep

OLAPARIB CBLC

Interaction Score: 4.58

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type osteosarcoma

Response Type predicted – sensitive

Approval Status Preclinical

PMIDs:
25883215

Sources:
JAX-CKB
OLAPARIB BRCA2

Interaction Score: 2.47

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type ovarian cancer

Response Type sensitive

Approval Status Preclinical - Pdx

PMIDs:
32043779 28792849 21862407 25218906 19553641 25366685 28578601 26510020 23346317 26546619 26116172 20609467 21097693 322 15 75 1682772 31157963 30345884 24882434 32343890 30797618

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC PharmGKB OncoKB
OLAPARIB PALB2

Interaction Score: 2.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26510020 32343890

Sources:
CIViC
OLAPARIB PARP1

Interaction Score: 1.91

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PARP 1, 2 & 3 inhibitor

Direct Interaction yes

PMIDs:
25981132 18800822 26650448 28454547 25144364

Sources:
DTC MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CIViC
OLAPARIB BARD1

Interaction Score: 1.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27197561 28389374

Sources:
CIViC
OLAPARIB PARP2

Interaction Score: 1.31

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PARP 1, 2 & 3 inhibitor

PMIDs:
25981132

Sources:
MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions
OLAPARIB BAP1

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28389374 22683710

Sources:
CIViC
OLAPARIB PARP3

Interaction Score: 0.92

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PARP 1, 2 & 3 inhibitor

Direct Interaction yes

PMIDs:
25981132

Sources:
ChemblInteractions
OLAPARIB STAG2

Interaction Score: 0.86

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
21852505 24356817

Sources:
JAX-CKB
OLAPARIB IDH2

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28148839

Sources:
CIViC
OLAPARIB CDK12

Interaction Score: 0.57

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24240700

Sources:
CIViC
OLAPARIB ATM

Interaction Score: 0.55

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung adenocarcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
24841718 26510020 20124459 20739657 26282658 28363999 8 2014 32343890

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC OncoKB
OLAPARIB BRCA1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type breast cancer

Response Type sensitive

Approval Status Phase II

PMIDs:
26546619 22172724 27454287 25193512 25366685 20609467 28792849 21862407 25218906 19553641 28578601 23346317 31157963 30797618 30345884 24882434 31538027

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC PharmGKB OncoKB
OLAPARIB VHL

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BPTES + Olaparib

Indication/Tumor Type renal cell carcinoma

Response Type sensitive

PMIDs:
28346230

Sources:
JAX-CKB
OLAPARIB ATR

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
OLAPARIB CHEK1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28490518

Sources:
CIViC
OLAPARIB MYC

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28490518

Sources:
CIViC
OLAPARIB PGR

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
OLAPARIB ERBB2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Her2-receptor negative breast cancer

Response Type predicted – sensitive

Approval Status Phase III

PMIDs:
None found

Sources:
JAX-CKB PharmGKB FDA
OLAPARIB MET

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
26779812

Sources:
JAX-CKB
OLAPARIB ESR2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
OLAPARIB KRAS

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
28363999

Sources:
JAX-CKB
OLAPARIB PIK3CA

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BKM120 + Olaparib

Indication/Tumor Type ovarian cancer

Response Type sensitive

PMIDs:
26909613

Sources:
JAX-CKB
OLAPARIB PTEN

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD6482 + Olaparib

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

PMIDs:
None found

Sources:
JAX-CKB
OLAPARIB ESR1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
OLAPARIB IDH1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
28148839

Sources:
JAX-CKB CIViC
OLAPARIB TP53

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type breast cancer

Response Type decreased response

Approval Status Preclinical

PMIDs:
22172724

Sources:
JAX-CKB

MyCancerGenome: OLAPARIB
- Version: 20-Jun-2017
Alternate Names:

AZD2281 Development Name

OLAPARIB Generic Name

LYNPARZA Trade Name

Drug Info:

Drug Class Small molecule inhibitor

FDA Approval Ovarian cancer (with BRCA mutation)

Publications:
DTC: OLAPARIB
- Version: 02-September-2020
Alternate Names:

CHEMBL521686 ChEMBL Drug ID

Drug Info:

Publications:

Menear et al., 2008, 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1., J. Med. Chem.

JAX-CKB: Olaparib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Wang et al., 2016, Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer., Oncotarget

Frankum et al., 2015, Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity., Oncotarget

Weston et al., 2010, The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo., Blood

CIViC: OLAPARIB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Golan T et al., 2019, Maintenance Olaparib for Germline <i>BRCA</i>-Mutated Metastatic Pancreatic Cancer., N Engl J Med

Goff, 2013, Advanced ovarian cancer: what should be the standard of care?, J Gynecol Oncol

Moore K et al., 2018, Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer., N Engl J Med

TTD: Olaparib
- Version: 2020.06.01
Alternate Names:

D0J9HW TTD Drug ID

Drug Info:

Publications:
TALC: OLAPARIB
- Version: 12-May-2016
Alternate Names:

OLAPARIB Primary Drug Name

OLAPARIB Drug Generic Name

AZD2281 Drug Synonym

Drug Info:

Publications:
ChemblInteractions: CHEMBL521686
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
PharmGKB: olaparib
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL521686
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: OLAPARIB
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: OLAPARIB
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
OncoKB: Olaparib
- Version: 23-July-2020
Alternate Names:

Drug Info:

Publications:
FDA: Olaparib
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Indication/Tumor Type	osteosarcoma
Response Type	predicted – sensitive
Approval Status	Preclinical

Indication/Tumor Type	ovarian cancer
Response Type	sensitive
Approval Status	Preclinical - Pdx

Mechanism of Interaction	PARP 1, 2 & 3 inhibitor
Direct Interaction	yes

Indication/Tumor Type	glioblastoma multiforme
Response Type	sensitive
Approval Status	Preclinical - Cell culture

Indication/Tumor Type	lung adenocarcinoma
Response Type	sensitive
Approval Status	Preclinical

Indication/Tumor Type	breast cancer
Response Type	sensitive
Approval Status	Phase II

combination therapy	BPTES + Olaparib
Indication/Tumor Type	renal cell carcinoma
Response Type	sensitive

Indication/Tumor Type	Her2-receptor negative breast cancer
Response Type	predicted – sensitive
Approval Status	Phase III

Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	sensitive
Approval Status	Preclinical

Evidence Type	Actionable
Approval Status	Preclinical
Response Type	sensitive

combination therapy	BKM120 + Olaparib
Indication/Tumor Type	ovarian cancer
Response Type	sensitive

combination therapy	AZD6482 + Olaparib
Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	sensitive

Indication/Tumor Type	Advanced Solid Tumor
Response Type	sensitive
Approval Status	Preclinical - Cell culture

AZD2281	Development Name
OLAPARIB	Generic Name
LYNPARZA	Trade Name

OLAPARIB	Primary Drug Name
OLAPARIB	Drug Generic Name
AZD2281	Drug Synonym

OLAPARIB Drug Record

OLAPARIB chembl:CHEMBL521686 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type osteosarcoma Response Type predicted – sensitive Approval Status Preclinical

PMIDs: 25883215

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type ovarian cancer Response Type sensitive Approval Status Preclinical - Pdx

PMIDs: 32043779 28792849 21862407 25218906 19553641 25366685 28578601 26510020 23346317 26546619 26116172 20609467 21097693 322 15 75 1682772 31157963 30345884 24882434 32343890 30797618

Sources: ClearityFoundationBiomarkers JAX-CKB CIViC PharmGKB OncoKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26510020 32343890

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction PARP 1, 2 & 3 inhibitor Direct Interaction yes

PMIDs: 25981132 18800822 26650448 28454547 25144364

Sources: DTC MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27197561 28389374

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction PARP 1, 2 & 3 inhibitor

PMIDs: 25981132

Sources: MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28389374 22683710

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction PARP 1, 2 & 3 inhibitor Direct Interaction yes

PMIDs: 25981132

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type glioblastoma multiforme Response Type sensitive Approval Status Preclinical - Cell culture

PMIDs: 21852505 24356817

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28148839

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24240700

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type lung adenocarcinoma Response Type sensitive Approval Status Preclinical

PMIDs: 24841718 26510020 20124459 20739657 26282658 28363999 8 2014 32343890

Sources: ClearityFoundationBiomarkers JAX-CKB CIViC OncoKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type breast cancer Response Type sensitive Approval Status Phase II

PMIDs: 26546619 22172724 27454287 25193512 25366685 20609467 28792849 21862407 25218906 19553641 28578601 23346317 31157963 30797618 30345884 24882434 31538027

Sources: ClearityFoundationBiomarkers JAX-CKB CIViC PharmGKB OncoKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy BPTES + Olaparib Indication/Tumor Type renal cell carcinoma Response Type sensitive

PMIDs: 28346230

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationBiomarkers

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28490518

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28490518

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type Her2-receptor negative breast cancer Response Type predicted – sensitive Approval Status Phase III

PMIDs: None found

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type osteosarcoma

Response Type predicted – sensitive

Approval Status Preclinical

PMIDs:
25883215

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type ovarian cancer

Response Type sensitive

Approval Status Preclinical - Pdx

PMIDs:
32043779 28792849 21862407 25218906 19553641 25366685 28578601 26510020 23346317 26546619 26116172 20609467 21097693 322 15 75 1682772 31157963 30345884 24882434 32343890 30797618

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC PharmGKB OncoKB

Interaction Types & Directionality:

n/a

PMIDs:
26510020 32343890

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PARP 1, 2 & 3 inhibitor

Direct Interaction yes

PMIDs:
25981132 18800822 26650448 28454547 25144364

Sources:
DTC MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CIViC

Interaction Types & Directionality:

n/a

PMIDs:
27197561 28389374

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PARP 1, 2 & 3 inhibitor

PMIDs:
25981132

Sources:
MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
28389374 22683710

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PARP 1, 2 & 3 inhibitor

Direct Interaction yes

PMIDs:
25981132

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
21852505 24356817

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
28148839

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
24240700

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung adenocarcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
24841718 26510020 20124459 20739657 26282658 28363999 8 2014 32343890

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC OncoKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type breast cancer

Response Type sensitive

Approval Status Phase II

PMIDs:
26546619 22172724 27454287 25193512 25366685 20609467 28792849 21862407 25218906 19553641 28578601 23346317 31157963 30797618 30345884 24882434 31538027

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC PharmGKB OncoKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BPTES + Olaparib

Indication/Tumor Type renal cell carcinoma

Response Type sensitive

PMIDs:
28346230

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers

Interaction Types & Directionality:

n/a

PMIDs:
28490518

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
28490518

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Her2-receptor negative breast cancer

Response Type predicted – sensitive

Approval Status Phase III

PMIDs:
None found

Sources:
JAX-CKB PharmGKB FDA

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
26779812

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
28363999

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BKM120 + Olaparib

Indication/Tumor Type ovarian cancer

Response Type sensitive